The Importance of Anticipating Risk
This article was originally published in SRA
Executive Summary
Three months ago, in May 2006, the US Food and Drug Administration (FDA) asked manufacturers of attention deficit hyperactivity disorder drugs to strengthen the warnings on the labels of their products to highlight the risk of serious cardiovascular and psychiatric events. Similarly, in 2004, the agency asked manufacturers of anti-depressants to add boxed warnings to their products about the increased risk of suicidal behaviour in children and adolescents. One might reasonably ask, “Why now?” Most of these drugs have been on the market for years (in one case more than 20 years) and in some cases prescribed to very large numbers of people, including for off-label use. The answer is that until recently, the regulatory community didn't look at the risk profile of a drug over time and in the context of different users. Now it does. And it's about time.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.